Evidence map›Paper›PMID 20518718›Full record

ReviewExpert review of vaccines2010

Development and application of 'phosphoflow' as a tool for immunomonitoring.

Sheng Wu, Lei Jin, Luis Vence, Laszlo G Radvanyi

Open access · greenAbstract readReview
In one paragraph

Review in Expert review of vaccines, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 55 citations in OpenAlex.

  1. Article
  2. Case Report: NovelFrontiers in immunology · 2025
    Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Imaging flow cytometry: coping with heterogeneity in biological systems.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2012
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Sheng WuDepartment of Melanoma Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.
Lei Jin
Luis Vence
Laszlo G Radvanyi
The University of Texas MD Anderson Cancer Center · USMelanoma Institute Australia · AU

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Molecular Mechanisms of pDC InteractionsP01CA128913 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HWU, PATRICK · 2008 to 2012
$9.3M
DC Vaccination to Enhance Adoptive T Cell TransferR01CA111999 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HWU, PATRICK · 2006 to 2010
$1.8M
NCI NIH HHS 5P30 CA016672 31NCI NIH HHS 5R01 CA111999 04NCI NIH HHS P01 CA128913NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Flow cytometry has revolutionized our ability to monitor immune responses by allowing us to simultaneously track a variety of cell surface and intracellular markers in discrete cell subsets in a highly sensitive and reproducible manner. This is especially critical in this new era of vaccinology trying to tackle the growing problems of chronic viral infections and cancer that not only evade host immune responses, but can negatively manipulate vaccine-induced immune responses. Thus, understanding how lymphocyte signaling is altered under normal and pathological conditions has become more critical. Over the last decade, a new flow cytometry technology called 'phosphoflow' (also sometimes called 'phosflow'), is rapidly developing for tracking multiple intracellular signaling molecules in the immune system at a single-cell level. Antibodies and reagents for tracking both tyrosine-phosphorylated and serine/threonine-phosphorylated signaling intermediaries in key immune signaling pathways have been developed, and phosphoflow is now starting to be applied to a wide variety of both preclinical and clinical studies on lymphocyte responses, as well as the functioning of cancer cells and virally infected cells. Here, we review the development of phosphoflow technology, its modern applications in the field of immunomonitoring and its current limitations. We then provide a perspective on the future of phosphoflow and a vision of how it can be applied to emerging critical questions in human vaccinology and public health.

Indexed as

Cytotoxicity, ImmunologicAnimalsCancer VaccinesFlow CytometryHumansT-Lymphocytes, CytotoxicCancer Vaccines

Identifiers

PMID20518718
PMCPMC2933839
OpenAlexW2146171937

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.